Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 1 Million USD | 97.98% |
| 2021 | 509 Thousand USD | 244.3% |
| 2020 | -352.73 Thousand USD | 55.18% |
| 2019 | -787.08 Thousand USD | 0.0% |
| 2017 | -2.29 Million USD | -134.56% |
| 2016 | -979.64 Thousand USD | 15.52% |
| 2015 | -1.15 Million USD | 56.72% |
| 2014 | -2.67 Million USD | 43.19% |
| 2013 | -4.71 Million USD | 37.72% |
| 2012 | -7.57 Million USD | -61.15% |
| 2011 | -4.69 Million USD | 44.41% |
| 2010 | -8.45 Million USD | -17.12% |
| 2009 | -7.21 Million USD | -128.03% |
| 2008 | -3.16 Million USD | 50.73% |
| 2007 | -6.42 Million USD | 70.27% |
| 2006 | -21.6 Million USD | -442.27% |
| 2005 | -3.98 Million USD | -18578.17% |
| 2004 | -21.33 Thousand USD | -116.74% |
| 2003 | 127.4 Thousand USD | -89.39% |
| 2002 | 1.2 Million USD | 72.93% |
| 2001 | 694.69 Thousand USD | 249.61% |
| 2000 | -464.35 Thousand USD | 77.89% |
| 1999 | -2.1 Million USD | -754.66% |
| 1998 | 320.81 Thousand USD | 449.01% |
| 1997 | -91.92 Thousand USD | 80.5% |
| 1996 | -471.42 Thousand USD | 43.76% |
| 1995 | -838.16 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 1.04 Million USD | 14.4% |
| 2023 Q1 | 1.12 Million USD | 12.06% |
| 2023 Q2 | 913.22 Thousand USD | -19.13% |
| 2022 Q3 | 808.06 Thousand USD | -14.95% |
| 2022 Q4 | 1 Million USD | 24.71% |
| 2022 FY | 1 Million USD | 97.98% |
| 2022 Q1 | 733.68 Thousand USD | 44.14% |
| 2022 Q2 | 950.05 Thousand USD | 29.49% |
| 2021 Q3 | 316.71 Thousand USD | 679.52% |
| 2021 Q4 | 509 Thousand USD | 60.72% |
| 2021 FY | 509 Thousand USD | 244.3% |
| 2021 Q1 | -210 Thousand USD | 49.09% |
| 2021 Q2 | 40.62 Thousand USD | 119.35% |
| 2020 Q2 | -571.92 Thousand USD | 23.62% |
| 2020 Q4 | -412.52 Thousand USD | -10.48% |
| 2020 FY | -352.73 Thousand USD | 55.18% |
| 2020 Q1 | -748.82 Thousand USD | 22.24% |
| 2020 Q3 | -373.37 Thousand USD | 34.72% |
| 2019 FY | -787.08 Thousand USD | 0.0% |
| 2019 Q2 | -787.08 Thousand USD | 55.44% |
| 2019 Q3 | -738.66 Thousand USD | 6.15% |
| 2019 Q4 | -962.94 Thousand USD | -30.36% |
| 2019 Q1 | -1.76 Million USD | 5.71% |
| 2018 Q2 | -2.29 Million USD | -27.15% |
| 2018 Q4 | -1.87 Million USD | 8.07% |
| 2018 Q3 | -2.03 Million USD | 11.33% |
| 2018 Q1 | -1.8 Million USD | -305.95% |
| 2017 Q1 | -1.81 Million USD | 13.4% |
| 2017 Q4 | -445.19 Thousand USD | -77.59% |
| 2017 Q2 | -979.64 Thousand USD | 46.05% |
| 2017 Q3 | -250.69 Thousand USD | 74.41% |
| 2017 FY | -2.29 Million USD | -134.56% |
| 2016 FY | -979.64 Thousand USD | 15.52% |
| 2016 Q1 | -1.51 Million USD | 19.11% |
| 2016 Q4 | -2.09 Million USD | -112.28% |
| 2016 Q3 | -987.67 Thousand USD | 14.82% |
| 2016 Q2 | -1.15 Million USD | 23.67% |
| 2015 FY | -1.15 Million USD | 56.72% |
| 2015 Q1 | -3.01 Million USD | 16.72% |
| 2015 Q4 | -1.87 Million USD | 12.4% |
| 2015 Q2 | -2.67 Million USD | 11.06% |
| 2015 Q3 | -2.14 Million USD | 19.98% |
| 2014 FY | -2.67 Million USD | 43.19% |
| 2014 Q3 | -4.44 Million USD | 5.66% |
| 2014 Q4 | -3.61 Million USD | 18.7% |
| 2014 Q1 | -5.86 Million USD | 7.75% |
| 2014 Q2 | -4.71 Million USD | 19.55% |
| 2013 Q1 | -4.87 Million USD | -60.26% |
| 2013 FY | -4.71 Million USD | 37.72% |
| 2013 Q2 | -7.57 Million USD | -55.24% |
| 2013 Q4 | -6.35 Million USD | 9.98% |
| 2013 Q3 | -7.05 Million USD | 6.79% |
| 2012 Q1 | -6.46 Million USD | -13.67% |
| 2012 Q3 | -4.42 Million USD | 5.84% |
| 2012 FY | -7.57 Million USD | -61.15% |
| 2012 Q4 | -3.04 Million USD | 31.21% |
| 2012 Q2 | -4.69 Million USD | 27.32% |
| 2011 Q4 | -5.68 Million USD | -6.6% |
| 2011 FY | -4.69 Million USD | 44.41% |
| 2011 Q3 | -5.33 Million USD | 36.88% |
| 2011 Q2 | -8.45 Million USD | 17.62% |
| 2011 Q1 | -10.26 Million USD | 1.53% |
| 2010 FY | -8.45 Million USD | -17.12% |
| 2010 Q2 | -7.21 Million USD | -32.5% |
| 2010 Q3 | -6.86 Million USD | 4.84% |
| 2010 Q1 | -5.44 Million USD | 35.85% |
| 2010 Q4 | -10.42 Million USD | -51.73% |
| 2009 Q2 | -3.16 Million USD | 20.14% |
| 2009 Q3 | -5.14 Million USD | -62.41% |
| 2009 Q4 | -8.49 Million USD | -65.17% |
| 2009 Q1 | -3.96 Million USD | 5.67% |
| 2009 FY | -7.21 Million USD | -128.03% |
| 2008 Q2 | -6.42 Million USD | 15.05% |
| 2008 FY | -3.16 Million USD | 50.73% |
| 2008 Q1 | -7.56 Million USD | 0.19% |
| 2008 Q4 | -4.2 Million USD | 49.31% |
| 2008 Q3 | -8.28 Million USD | -29.04% |
| 2007 Q3 | -15.58 Million USD | 27.88% |
| 2007 FY | -6.42 Million USD | 70.27% |
| 2007 Q4 | -7.57 Million USD | 51.38% |
| 2007 Q1 | -15.38 Million USD | -31.32% |
| 2007 Q2 | -21.6 Million USD | -40.4% |
| 2006 Q1 | -20.47 Million USD | -163.8% |
| 2006 Q4 | -11.71 Million USD | -21.06% |
| 2006 Q3 | -9.67 Million USD | -142.95% |
| 2006 Q2 | -3.98 Million USD | 80.54% |
| 2006 FY | -21.6 Million USD | -442.27% |
| 2005 FY | -3.98 Million USD | -18578.17% |
| 2005 Q4 | -7.76 Million USD | 12.31% |
| 2005 Q3 | -8.85 Million USD | -41403.52% |
| 2005 Q2 | -21.33 Thousand USD | 95.51% |
| 2005 Q1 | -475.47 Thousand USD | -204.16% |
| 2004 FY | -21.33 Thousand USD | -116.74% |
| 2004 Q4 | 456.47 Thousand USD | -20.63% |
| 2004 Q1 | 874.09 Thousand USD | -24.38% |
| 2004 Q2 | 127.4 Thousand USD | -85.42% |
| 2004 Q3 | 575.14 Thousand USD | 351.42% |
| 2003 Q4 | 1.15 Million USD | -6.72% |
| 2003 Q3 | 1.23 Million USD | 3.16% |
| 2003 Q2 | 1.2 Million USD | -1.68% |
| 2003 Q1 | 1.22 Million USD | 14.46% |
| 2003 FY | 127.4 Thousand USD | -89.39% |
| 2002 FY | 1.2 Million USD | 72.93% |
| 2002 Q3 | 607.99 Thousand USD | -12.48% |
| 2002 Q1 | 739.79 Thousand USD | 463.74% |
| 2002 Q2 | 694.69 Thousand USD | -6.1% |
| 2002 Q4 | 1.06 Million USD | 75.56% |
| 2001 Q4 | 131.22 Thousand USD | 536.22% |
| 2001 FY | 694.69 Thousand USD | 249.61% |
| 2001 Q1 | -164.04 Thousand USD | 84.72% |
| 2001 Q2 | -464.35 Thousand USD | -183.06% |
| 2001 Q3 | -30.08 Thousand USD | 93.52% |
| 2000 FY | -464.35 Thousand USD | 77.89% |
| 2000 Q3 | -677.62 Thousand USD | 67.74% |
| 2000 Q2 | -2.1 Million USD | 30.02% |
| 2000 Q4 | -1.07 Million USD | -58.47% |
| 2000 Q1 | -3 Million USD | -663.2% |
| 1999 Q3 | 374.54 Thousand USD | 0.0% |
| 1999 FY | -2.1 Million USD | -754.66% |
| 1999 Q4 | 532.89 Thousand USD | 42.28% |
| 1998 FY | 320.81 Thousand USD | 449.01% |
| 1997 FY | -91.92 Thousand USD | 80.5% |
| 1996 FY | -471.42 Thousand USD | 43.76% |
| 1995 FY | -838.16 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 77024.885% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 82.159% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.645% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 503.7% |
| Rebus Holdings, Inc. | 305 Thousand USD | -230.399% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 115.984% |
| Qrons Inc. | 351.42 Thousand USD | -186.75% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -61.917% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.68% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 5037.848% |
| Skye Bioscience, Inc. | -5.72 Million USD | 117.613% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 93.607% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 75.529% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -150.77% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.781% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 55.057% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -8.685% |
| Mesoblast Limited | 55.85 Million USD | 98.196% |
| Marizyme, Inc. | 18.56 Million USD | 94.573% |
| Genus plc | 190.6 Million USD | 99.471% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 54.929% |
| Pharming Group N.V. | 109.8 Million USD | 99.082% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -17.143% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 16.984% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -48.194% |
| ContraFect Corporation | -6.02 Million USD | 116.723% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -648.458% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 12.784% |
| IMV Inc. | 7.67 Million USD | 86.862% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 81.684% |
| MultiCell Technologies, Inc. | 90.04 USD | -1119087.028% |
| ONE Bio Corp. | 9.04 Million USD | 88.853% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 237.295% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 92.216% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 26.335% |
| Q BioMed Inc. | 4.06 Million USD | 75.179% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.702% |
| Biomind Labs Inc. | 711.4 Thousand USD | -41.652% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.336% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 49.599% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 92.131% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -180.147% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -620.806% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -4972.311% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 54.236% |
| GB Sciences, Inc. | 1.74 Million USD | 42.328% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 648.303% |
| HST Global, Inc. | 96.79 Thousand USD | -941.104% |
| CSL Limited | 10.52 Billion USD | 99.99% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -388.668% |
| Halberd Corporation | 144.72 Thousand USD | -596.316% |
| Enzolytics Inc. | 981.65 Thousand USD | -2.655% |
| Agentix Corp. | 37.63 Thousand USD | -2577.888% |
| Resverlogix Corp. | 6.45 Million USD | 84.379% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 249.715% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.05% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.144% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 85.749% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 62.796% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 111.4% |
| AVAX Technologies, Inc. | -5.9 Million USD | 117.071% |
| Zenith Capital Corp. | 10.06 Thousand USD | -9913.076% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.095% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -402.772% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 57.766% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -512.56% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 5601.234% |
| Kadimastem Ltd | -253.1 Thousand USD | 498.146% |
| Helix BioMedix, Inc. | -2.57 Million USD | 139.21% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 95.03% |
| BioStem Technologies, Inc. | 4.47 Million USD | 77.466% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -400.718% |
| LadRx Corporation | -2.03 Million USD | 149.483% |
| Cell Source, Inc. | 9.23 Million USD | 89.084% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -58.654% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -58.654% |
| NovAccess Global Inc. | 2.17 Million USD | 53.742% |
| Affymax, Inc. | -5.59 Million USD | 118.005% |
| Itoco Inc. | 228.3 Thousand USD | -341.39% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -641.028% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 79.671% |
| Mobile Lads Corp. | 484.23 Thousand USD | -108.106% |
| CytoDyn Inc. | 20.26 Million USD | 95.027% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 155852.087% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 10972.67% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 86.923% |
| SYBLEU INC | 473.71 Thousand USD | -112.727% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 77.39% |
| International Stem Cell Corporation | 2.59 Million USD | 61.092% |
| Bioxytran, Inc. | 1.89 Million USD | 46.932% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1514.593% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 53.794% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 70.655% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 88.218% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -30.431% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 180.617% |
| Neutra Corp. | 52.18 Thousand USD | -1830.971% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 140.487% |
| PureTech Health plc | -167.19 Million USD | 100.603% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 511.467% |
| IXICO plc | -4.44 Million USD | 122.673% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 92.377% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.163% |
| CSL Limited | 10.52 Billion USD | 99.99% |
| Cellectis S.A. | -43.81 Million USD | 102.3% |